You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

CLINICAL TRIALS PROFILE FOR ECONAZOLE NITRATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Econazole Nitrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00768599 ↗ A Study of Econazole Foam 1% in Athlete's Foot Completed AmDerma Phase 2 2008-03-01 This is a 6-week clinical study (4 weeks of treatment, once per day, plus a 2-week follow-up period) of a topical foam to treat athlete's foot. The active ingredient in the foam -- econazole nitrate 1% -- is the same active pharmaceutical ingredient in a cream that your doctor can currently prescribe to treat athlete's foot. This study will help to understand if the foam works the same as the cream to treat athlete's foot.
NCT01353976 ↗ Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed AmDerma Pharmaceuticals, LLC Phase 3 2011-05-01 This is a study of the safety and efficacy of topical Econazole Nitrate Foam 1% and the foam vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes). This is a 6 week study which has a 4 week treatment period and a 2 week follow-up evaluation.
NCT01353976 ↗ Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed AmDerma Phase 3 2011-05-01 This is a study of the safety and efficacy of topical Econazole Nitrate Foam 1% and the foam vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes). This is a 6 week study which has a 4 week treatment period and a 2 week follow-up evaluation.
NCT01358240 ↗ Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Completed AmDerma Pharmaceuticals, LLC Phase 3 2011-06-01 This is a study of the safety and efficacy of Econazole Nitrate Foam 1% and the Foam Vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes). This is a 6 week study which has a 4 week treatment period and a 2 week follow-up evaluation. The study will also utilize Econazole Nitrate Cream 1% (for safety comparison) and a Placebo cream for blinding purposes only.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Econazole Nitrate

Condition Name

Condition Name for Econazole Nitrate
Intervention Trials
Tinea Pedis 4
Athlete's Foot 3
Healthy 1
Healthy Women 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Econazole Nitrate
Intervention Trials
Tinea Pedis 5
Tinea 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Econazole Nitrate

Trials by Country

Trials by Country for Econazole Nitrate
Location Trials
United States 24
Switzerland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Econazole Nitrate
Location Trials
Texas 3
Tennessee 3
California 3
Florida 2
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Econazole Nitrate

Clinical Trial Phase

Clinical Trial Phase for Econazole Nitrate
Clinical Trial Phase Trials
Phase 3 3
Phase 2 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Econazole Nitrate
Clinical Trial Phase Trials
Completed 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Econazole Nitrate

Sponsor Name

Sponsor Name for Econazole Nitrate
Sponsor Trials
AmDerma 4
AmDerma Pharmaceuticals, LLC 3
Cross Research S.A. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Econazole Nitrate
Sponsor Trials
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Econazole Nitrate: Clinical Trials, Market Analysis, and Projections

Last updated: January 7, 2025

Clinical Trials and Efficacy

Econazole nitrate, an antifungal agent, has undergone extensive clinical trials to establish its efficacy and safety.

Interdigital Tinea Pedis Trials

In two Phase 3 multi-center, randomized, double-blind, vehicle-controlled trials, econazole nitrate foam (1%) was evaluated for the treatment of interdigital tinea pedis. These trials involved 505 subjects, with 339 having a positive fungal culture. The results showed that econazole nitrate foam was effective in achieving clinical and mycological cure rates. The primary endpoint of "Complete Cure" at day 43 was met, with subjects showing no signs and symptoms, negative KOH, and negative culture results[1][3].

Safety Profile

The safety findings from these trials were favorable, with similar safety profiles observed in both adolescent and adult populations. Only 3% of patients treated with econazole nitrate 1% cream reported side effects, which were generally mild and included headaches and nasopharyngitis. No serious adverse events, deaths, or pregnancies were reported during the trials[1][3].

Pediatric Use

A Phase 2 pediatric pharmacokinetic trial conducted in subjects aged 12-17 years with interdigital tinea pedis provided additional safety data, and no safety concerns were identified. This data supported the extrapolation of efficacy from the adult population to adolescents[3].

Market Analysis

Global Market Overview

The global econazole nitrate market is driven by several key factors, including the increasing prevalence of fungal infections such as tinea pedis, ringworm, and jock itch.

Market Segments

The market is segmented by type (e.g., 15g, 30g, 85g, 120g) and application (e.g., ringworm of the body, jock itch, tinea pedis, tinea versicolor). The report provides a detailed breakdown of these segments, highlighting their lucrativeness and growth potential[2].

Key Players

Major players in the econazole nitrate market include Mylan, Perrigo Israel, Taro Pharmaceutical Industries Ltd., Teligent Pharma Inc., Alvogen, and Bide Pharmatech Ltd. These companies employ various strategies to maintain their market positions, including product offerings, recent developments, and financial strategies[2].

Market Drivers

The increasing cases of obesity, binge eating, and lack of regular exercise contribute to the rising demand for antifungal treatments. Stress and poor lifestyle choices also play a significant role in driving the market growth. Additionally, the widespread prevalence of fungal infections globally is a key driver[2].

Market Projections

Forecast and Growth

The global econazole nitrate cream market is expected to grow significantly over the forecast period of 2022-2030. The market research reports provide quantitative analyses and revenue forecasts, helping industry players to strategize and grow in the market. The projected revenue figures and sales data by type and application segments are crucial for understanding the market's future trajectory[2][5].

Regional Analysis

The market analysis includes a detailed overview of various regions and countries, focusing on demand and supply dynamics. This regional analysis helps in understanding the market's expansion and identifying opportunities for growth in different geographical areas[2].

Competitive Landscape

The competitive landscape of the econazole nitrate market is highly competitive, with key players vying for market share. The report provides insights into the market revenue shares of these players and their business strategies, which is essential for understanding the competitive outlook of the industry[2].

Drug Interactions and Postmarket Requirements

Potential Drug Interactions

There have been reports of drug interactions between econazole nitrate and warfarin, particularly in elderly patients. These interactions can lead to increased systemic absorption of econazole nitrate, affecting anticoagulation status. To address this, postmarketing requirements include in vitro assessments to evaluate the inhibition and induction potential of econazole nitrate on various cytochrome P450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4)[1].

Postmarket Risk Evaluation

No postmarketing Risk Evaluation and Mitigation Strategies (REMS) are recommended, as the labeling is considered adequate to inform prescribers about potential risks and interactions[1].

Key Takeaways

  • Efficacy and Safety: Econazole nitrate foam has demonstrated high efficacy and a favorable safety profile in treating interdigital tinea pedis.
  • Market Growth: The global econazole nitrate market is driven by increasing fungal infections and lifestyle factors, with significant growth projected over the next few years.
  • Key Players: Major pharmaceutical companies are key players in the market, employing various strategies to maintain their market positions.
  • Drug Interactions: Potential drug interactions, particularly with warfarin, necessitate postmarketing assessments to ensure patient safety.
  • Regional Analysis: The market's growth varies by region, with detailed analyses providing insights into demand and supply dynamics.

FAQs

What is the primary use of econazole nitrate?

Econazole nitrate is primarily used to treat various fungal infections, including interdigital tinea pedis, ringworm, jock itch, and tinea versicolor.

What are the common side effects of econazole nitrate?

Common side effects are generally mild and include headaches and nasopharyngitis, affecting about 3% of patients.

Which companies are major players in the econazole nitrate market?

Key players include Mylan, Perrigo Israel, Taro Pharmaceutical Industries Ltd., Teligent Pharma Inc., Alvogen, and Bide Pharmatech Ltd.

What are the potential drug interactions with econazole nitrate?

Econazole nitrate may interact with warfarin, particularly in elderly patients, affecting anticoagulation status.

What is the projected growth of the global econazole nitrate market?

The market is expected to grow significantly over the forecast period of 2022-2030, driven by increasing fungal infections and lifestyle factors.

Sources

  1. FDA: N205175 Econazole nitrate Clinical PREA.
  2. Biospace: Econazole Nitrate Cream Market Size, CAGR Status, Leading Trends and Forecast to 2030.
  3. FDA: Spectazole Ecoza Safety and Utilization Review.
  4. EudraCT: Phase III study to evaluate the efficacy of a novel antimycotic vaginal pessary combination.
  5. MarketResearchReports.com: Global Econazole Nitrate Market Research Report 2024.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.